[Treatments and outcome predictors in Guillain-Barré syndrome]

Guillain-Barré syndrome (GBS) is a heterogeneous disease, and has a various clinical course and outcome. Despite the use of standard therapies, such as plasma exchange or intravenous immunoglobulin therapy, some patients still have residual neurological sequelae. New therapies and treatment modalities may improve outcome in patients with poor recovery in the current standard therapies, if the patients with poor prognosis could be identified in early disease phase. In recent years, prognosis and potential determinants of clinical outcome in GBS have been investigated by various methods. The clinical prediction models using selected predictors (high age, preceding diarrhea, and low Medical Research Council sum score, and their combined scoreing systems, etc.) were advocated.